South Korea Car-T Cell Therapy Market ANALISI DIMENSIONE E QUOTA - TENDENZE DI CRESCITA E PREVISIONI (2024 - 2031)
South Korea Car-T Cell Therapy Market is Segmented By Targeted Antigen (CD19, CD20, BCMA, GCP-3, Claudin 18.2), By Therapeutic Application (B-cell non-Hodgkin\'s lymphoma, Multiple Myeloma, Cervical Cancer, Gastric Cancer, Lung Cancer, Others). The report offers the value (in USD Million) for the above-mentioned segments
Competitive overview of South Korea Car-T Cell Therapy Market
I principali attori operanti nel mercato della terapia cellulare della Corea del Sud includono Novartis AG, Pfizer, Inc., Bristol Myers Squibb, CARsgen Therapeutics Co., Ltd., Fate Therapeutics, Inc., Poseida Therapeutics, Inc., Eureka Therapeutics, Inc., Johnson & Johnson, Cellular Biomedicine Group, e Gilead Sciences.
South Korea Car-T Cell Therapy Market Leaders
- Novartis AG
- Pfizer, Inc.
- Bristol Myers Squibb
- CARsgen Therapeutics Co., Ltd.
- Fate terapeutica, Inc.
*Disclaimer: Major players are listed in no particular order.
South Korea Car-T Cell Therapy Market - Competitive Rivalry, 2023
South Korea Car-T Cell Therapy Market
Market Consolidated
(Dominated by major players)
(Dominated by major players)
Market Fragmented
(Highly competitive with lots of players.)
(Highly competitive with lots of players.)
*Source: Coherent Market Insights